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Abstract 
Antimicrobial resistance has during the last decades become a global public health problem. Metallo-
β-lactamases (MBLs) which are broad-spectrum β-lactamases that inactivate virtually all β-lactams 
including carbapenems, are contributing to this health problem. In this study a novel MBL variant, 
termed VIM-26, identified in a Klebsiella pneumoniae isolate was studied. VIM-26 belongs to the 
VIM-family of MBLs and is a His224Leu variant of the well-characterized VIM-1 variant. In this study, 
we report the kinetic parameters, minimum inhibitory concentrations (MICs) and crystal structures of 
a recombinant VIM-26 protein, and compare them to previously published data on VIM-1, VIM-2 and 
VIM-7. The kinetic parameters and MIC determinations show that VIM-26, like VIM-7 has higher 
penicillinase activity, but lower cephalosporinase activity than VIM-1 and VIM-2. The four 
determined VIM-26 crystal structures revealed mono- and di-zinc forms, where the Zn1 ion has 
distorted tetrahedral coordination geometry with an additional water molecule (W2) at a distance of 
2.6 to 3.7 Å, which could be important during catalysis. The R2 drug-binding site in VIM-26 is more 
open compared to VIM-2 and VIM-7, and neutrally charged due to Leu224 but also because of 
Ser228. Thus, the VIM-26 drug-binding properties are different than in the VIM-2 (Tyr224/Arg228) 
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Introduction 
Antimicrobial resistance is not a new problem, but the increasing prevalence of antimicrobial 
resistance and multidrug-resistant bacteria has resulted in a growing public health problem [1]. In 
Gram-negative bacteria, the emergence and dissemination of acquired carbapenemases such as 
metallo-β-lactamases (MBLs) are of particular concern [2, 3]. MBLs hydrolyzes and inactivates all β-
lactams including carbapenems with the exception of monobactams. The genes encoding MBLs are 
frequently located in mobile genetic structures facilitating dissemination and spread among Gram-
negative bacteria [3]. Further, bacterial isolates harboring MBLs are often co-resistant to other 
antimicrobial agents such as aminoglycosides, thus limiting treatment options [3, 4]. 
 
The Verona integron-encoded metallo-β-lactamase (VIM) family currently includes >40 different VIM 
genes (http://www.lahey.org/Studies/) divided in the VIM-1, VIM-2 and VIM-7 subgroups [5]. VIM-26 
was first reported in a clinical Klebsiella pneumoniae isolate from 2006 [6]. The isolate was found to 
be resistant to all β-lactams as well as aminoglycosides and ciprofloxacin and only susceptible to 
tigecycline and colistin [6]. VIM-26 differs from the well characterized VIM-1 by only one amino acid 
residue, a histidine to leucine substitution in position 224, and belongs to the VIM-1 subgroup. The 
amino acid sequence identity between VIM-26 and VIM-2 is 91%. Residue 224 is part of the loop 
including residues 223 to 240 named the L3 loop [7], L10 loop [8] or L2 loop [9, 10], and will herein be 
denoted the L3 loop. Mutagenesis studies of VIM-13 mutating Leu224 and Arg228 to His and Ser, 
respectively, as found in VIM-1, resulted in increased catalytic efficiency and elevated MIC values 
more similar to VIM-1, indicating the importance of the L3 loop [7]. In another study on VIM-23, 
which has just one amino acid difference compared to VIM-2, namely a serine at position 228 instead 
of an arginine as in VIM-2, a significant effect on MIC values in the same genetic background was 
observed with cephalosporins and ertapenem [11]. For other β-lactams the effect was similar 
between VIM-23 and VIM-2.  
 
Residue 224 in the L3 loop, is a conserved lysine in many B1 family MBLs and found be critical for 
binding the carboxyl group on the C-3/C-4 atom of the substrate [2, 8, 12]. In the VIM family of 
enzymes residue 224 is found to be either a histidine such as in VIM-1, VIM-4, VIM-7 and VIM-31, a 
tyrosine such as in VIM-2 or a leucine such as in VIM-5, VIM-13, VIM-26 and VIM-28. We previously 
proposed, based on analysis of the crystal structure and docking experiments, that the His224 in 
VIM-7 was a residue determinant partly responsible for the poor affinity to positively charged 
cephalosporins [9, 13]. This was explained by the presence of a more positively charged R2 binding 
pocket repelling a positively charged substrate. In addition there are two stabilizing hydrogen bonds 
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in VIM-2 involving Tyr224 [9]. We later confirmed this through structural and kinetic studies of a 
His224Tyr mutation of VIM-7 where we could show that the mutant was more active against 
positively charged cephalosporins compared to the wild type VIM-7 [14]. In a VIM-2 thiol based 
inhibitor complex it was found that both Arg228 and Asn233 are important for inhibitor binding and 
recognition [15]. The L3 loop of VIM-4 and VIM-7 include His224 and Arg228 in both enzymes [9, 16], 
where His224 has a similar conformation in both enzymes. Arg228, however, points towards Zn2 in 
VIM-4, but has a more open conformation in VIM-7. Residue 228 is Ser in VIM-26 and VIM-1, but Arg 
in VIM-2, VIM-4, VIM-7 and VIM-31. All these finding underline the importance of residue 224 for the 
enzymatic activity and substrate specificity for this family of MBLs. Another loop important for the 
substrate specificity is the L1 loop (residues 60-66) situated opposite to the L3 loop, for example as 
shown for GIM-1 [10]. 
 
To characterize VIM-26 and explore the influence of the residue composition of the L3 loop on 
activity, we made a recombinant version the enzyme and subsequently performed enzyme kinetics 
studies, microbiological testing and determined four three-dimensional structures based on 
crystallization of recombinant VIM-26. 
 
Results and discussion 
The VIM-family of MBLs is along with the New Delhi Metallo-β-lactamase (NDM) family the most 
prevalent and widespread MBLs globally [3, 17]. Inhibition of serine-β-lactamases has previously 
been used successfully to extend the life-time of β-lactam antibiotics [18]. Despite promising 
scientific results [19], there is currently no clinically available inhibitor for MBLs [20]. Consequently, 
studies into the biochemical and structural characteristics of MBLs are important for future inhibitor 
design. In this study we have investigated the characteristics of VIM-26, a member of the VIM-MBL-
family [6], in order to better understand the role of residue position 224 and particularly the L3 loop 
in substrate specificity. 
 
Enzymatic characterization and MIC determinations 
The steady state kinetic constants and MIC determinations for VIM-26 and the comparator enzymes 
(VIM-1, VIM-2 and VIM-7) are shown in Table 1 and Table 2, respectively. The kinetic experiments 
showed that recombinant VIM-26 hydrolyzes penicillins more efficiently than cephalosporins and 
carbapenems (Table 1; Figure 1). Among the penicillins tested we found that VIM-26 hydrolyzed 
benzylpenicillin more efficiently than ampicillin (Table 1). For the cephalosporins, VIM-26 was more 
efficient against cefuroxime compared to cefepime, ceftazidime and cefoxitin, mainly due to higher 
5 | P a g e  
 
affinity (lower KM) but also higher turnover (higher kcat) for the former. The relative carbapenemase 
activity of VIM-26 was similar between imipenem and meropenem, but slightly lower towards 
ertapenem, mainly due to lower affinity. The kinetic properties of VIM-26 were generally also 
observed in the MIC determinations with only marginal increases in the MIC to cefoxitin and 
ertapenem (Table 2).  
 
Compared to the other VIM-variants, the overall trend was that VIM-26 and periplasmic purified 
VIM-7 [14] were more efficient penicillinases than VIM-1 [21] and VIM-2 [22] (Table 1). In contrast 
both VIM-1 (all cephalosporins) and to a certain degree VIM-2 (ceftazidime and cefoxitin) were more 
efficient cephalosporinases than VIM-26 and VIM-7. This was also in general reflected in the MIC 
values for most substrates (Table 2) except for some discrepancies (e.g. VIM-2 and ceftazidime). 
Kinetic analysis of VIM-5 [23] and VIM-13 [7] which along with VIM-26 also possesses Leu224 showed 
lower cephalosporinase activity compared to VIM-1 and VIM-2. This suggests that Leu224 could be 
involved in the lower cephalosporinase activity of VIM-26 as observed for other VIM-variants with 
Leu224. The catalytic efficiencies against the different carbapenems were found to be slightly lower 
for VIM-26 compared to VIM-1, VIM-2 and VIM-7. Generally, this could be attributed to lower 
binding affinities for these substrates since the turnover (kcat) for VIM-26 against carbapenems were 
in many cases higher than for VIM-1, VIM-2 and VIM-7. It should be noted that the comparison of the 
kinetic properties of VIM-26 to other different VIM-variants were done using previously determined 
data from different laboratories. This could obviously influence the results. However, previous 
experience with VIM-2 revealed no major discrepancies with previously published values when 
tested under different experimental conditions (Samuelsen et al., 2008 [13]). Although the different 
VIM-genes were cloned into the same vector and E. coli background, the MIC values for some 
substrates did not correlate with the kinetic data. This could be due to several factors such as 
differences in enzyme expression, but could also indicate that in vitro determined properties do not 
always correlate to the in vivo setting.  
 
The VIM-26 crystal structures 
In order to gain further insight into the structure activity relationship of VIM-26, and to shed light on 
the role of Leu224 in the L3 loop, the crystal structure of the recombinant VIM-26 was solved (Figure 
2).  
 
From both cryo protected and inhibitor soaked crystals, we obtained in total four VIM-26 structures. 
The structures included one structure binding only one (Zn1) zinc ion (termed VIM-26-Mono), one 
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native structure (termed VIM-26) containing both the Zn1 (tri-histidine site) and Zn2 (Cys-His-Asp 
site) ions, one structure with an extra water molecule as the Zn1 ligand (termed VIM-26-W) and one 
structure with a PEG in the active site (termed VIM-26-PEG)(Figure 3). All structures are resolved to 
high resolution (1.55-1.70 Å), low R-factors (15.3-15.6%) and R-free values (18.2-20.0%) and 
satisfactory geometry (Table 3 and 4). The overall structure of VIM-26 showed, as expected, the 
characteristic / fold of MBLs, with the active site situated at the edge of the  sandwich 
flanked by two catalytically important loops on each side consisting of residue 60-66 (denoted L1) 
and 223-240 (denoted L3) (Figure 2a).  
 
The four VIM-26 structures had an RMDS value of 0.11-0.44 Å among each other for CA-atoms only, 
where VIM-26-Mono was the most diverse. Differences were found in the zinc binding sites of Zn1 
and Zn2 (Table 5). Cys221 was oxidized into cysteinesulfonic residue in all VIM-26 structures (termed 
Osc221, Figure 3). Oxidation of Cys221 has also been observed in other subclass B1 MBLs (GIM-1, 
BcII, SPM-1)[10, 24, 25], indicating that this cysteine is an oxidative sensitive residue. The oxidation is 
likely explained by lack of reducing agents during crystallization since addition of the reducing agent 
(e.g. TCEP and β-mercaptoethanol) resolved this issue for both the VIM-2 and VIM-7 crystal 
structures [9, 26]. Still radiation damage [27, 28] of Cys221 at the highly intense BL14.1 beamline at 
Bessy-II cannot be ruled out.  
 
The VIM-26-PEG structure was obtained after a soak with the inhibitor D-captopril but the extra 
electron density in the active site was interpreted as a PEG molecule and not the inhibitor. The PEG 
molecule is protruding into the R1 binding site where Trp87 is found in two conformations, but the 
overall structure is similar to the three other VIM-26 structures. 
 
Zinc binding in the metallo--lactamase VIM-26 
The Zn1 site in the four VIM-26 structures has either four (VIM-26, VIM-26-PEG) or five ligands (VIM-
26-Mono, VIM-26-W) since an extra water molecule (W2) is bridging Zn1 and Asn233 ND2 in the two 
latter (Figure 3). The hydrogen bond from W2 to Asn233 ND2 (3.46 Å VIM-26-Mono; 3.09 Å in VIM-
26-W) could be important for catalysis and/or substrate binding (Figure 3a, c). A similar water is 
found in the oxidised VIM-7 (PDB ID: 2Y8B)[9]. The role of residue 233 has been discussed as part of 
the substrate binding [29-32]. This residue is found to be asparagine in the majority of the B1 MBLs 
[31] including VIM-26, but is a tyrosine in other MBLs, for example in GIM-1 [10]. The fifth Zn1 ligand 
was found in both mono (VIM-26-Mono) and the di-zinc (VIM-26-W) forms, reflecting flexibility in the 
enzyme. The geometry of all Zn1 sites was tetrahedral (Table 5B) therefore the fifth Zn1 ligand could 
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resemble a carbonyl oxygen of an incoming substrate [9, 33]. A fifth Zn1 ligand is infrequently 
reported, but could be important here since it interacts with the partly conserved Asn233 residue in 
the L3 loop [31], the extra W2 water is adjacent the inhibitor bound to VIM-2 (PDB ID: 2YZ3; [15]), it 
interacts with the hydrolytic hydroxyl ion in-between two zinc ions and since water molecules are 
used in the hydrolyses of substrates and thus must be replaced during catalysis.  
 
The Zn2 ion was missing in the VIM-26-Mono structure as judged from the observed electron density, 
thus indicating a lower zinc affinity for the Zn2 binding site compared to the Zn1 site. For the three 
other VIM-26 structures the geometry and interatomic distances of the Zn2 ion are a distorted 
octahedron with the Zn2 ion in the center, His263 NE2 and W1/hydroxyl ion at the axial positions, 
and Asp120 OD2, Ocs221 OD2 and two water molecules (W3, W4) at the four equatorial positions. 
The metal-to-metal distances are between 3.60 Å (VIM-26, VIM-26-W) to 3.86 Å (VIM-26-PEG; Table 
5). The oxidised Cys221 has probably caused the reduced Zn2 occupancy (0.5 in VIM-26, 0.5 in VIM-
26-W; 0.3 in VIM-26-PEG). Overall, the four presented structures shed light on the structural 
variation, flexible architecture and different coordination geometry of the metal centers in VIM-26. 
Despite the overall good quality electron density maps in the determined VIM-26 structures, we 
cannot completely rule out that the oxidised Cys221 disturbs its local environment.   
 
The L1 loop  
The main chain conformations of the L1 loop in the four VIM-26 structures were similar, but in VIM-
26-Mono, the Gln59, Tyr67, His263, Trp87 and Asp119 residues were slightly shifted compared to the 
other structures. In the VIM-26-PEG structure, Trp87 was found in two different conformations. In 
the VIM-26-Mono structure Trp87 was slightly shifted and made a polar interaction with Asp119 OD2 
(Figure 2c), whereas the Gln59 side chain was involved in a hydrogen bound to both Ala86 O (2.89 Å 
from NE2) and to Asn91 ND2 (3.11 Å from OE1). In the three other VIM-26 structures Gln59 NE2 was 
hydrogen bound to Trp87 O and the Gln59 side chain was water exposed. Tyr67 in the L1 loop of 
VIM-26-Mono was clearly rotated towards Trp87, although the OH-atoms were not defined in the 
observed electron density maps. Residue 87 is a tryptophan in all VIM crystal structures, found in one 
main rotamer conformation (VIM-2, VIM-4, VIM-7 [9, 15, 16, 26] and VIM-31 (PDB ID 4FSB, 4FR7)), 
except in oxidised VIM-31 (PDB ID: 4FSB). For VIM-26 it is also one preferable Trp87 conformation, 
and the one in VIM-26-Mono (Figure 2c) is less frequent and influenced by the adjacent residues. The 
movements of residues Gln59, Tyr67, His263, Trp87 and Asp119 in VIM-26-Mono could be also linked 
to the missing Zn2 ion, since the crystal packing, unit cell and space group were similar for all four 
structures. 
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Implication of Leu224 in the L3 loop 
VIM-26 differs from VIM-1 by a single residue, namely histidine 224 which has been substituted with 
a leucine [6]. This residue is part of the L3 loop involved in the R2 substrate binding site, and plays an 
important role in catalysis [2, 7, 14]. All the VIM-26 structures showed an open binding site for the R2 
part of the substrates (Figure 4a). We found that the electrostatic surface around the active site of 
VIM-26 showed a more neutral R2 site compared to VIM-2 and VIM-7 (Figure 4a, b, c), and also 
compared to VIM-4 (data not shown). According to our analysis of the structure, the substitution of 
histidine to leucine at position 224 is mainly responsible for the neutral R2 site in VIM-26, but Ser228 
also contributes to generate a larger pocket. In both VIM-2 and VIM-7, residue 228 is arginine 
contributing to a narrower pocket. In two VIM-2 crystal structures, one apo-structure and one 
inhibitor bound (PDB ID: 1KO3 and 2YZ3, respectively) as well as in a VIM-7 structure (PDB ID: 2Y87), 
Arg228 are found in very different conformations [9, 15]. The mutation of His224 in VIM-7 into Tyr, 
to resemble the sequence of VIM-2, increased the thermal stability and enzyme activity of the 
mutant [14]. Furthermore, the enzymatic activity increased compared to wild type particularly 
towards the positively charged cephalosporins cefepime and ceftazidime [14], again underlining the 
importance of residue 224. Ser228 and Leu224 in VIM-26 make a very different binding site 
compared to Arg228 and Tyr/His224 in the other VIM structures (Figure 4a-c). The neutral residues in 
VIM-26 are also different from other B1 MBLs that have a conserved positively charged Lys224 in the 
R2 binding site [2, 8, 12], or Arg228 as in VIM-2 and VIM-7 structures [9, 15, 26]. This might explain 
the high KM (lower affinity) found for VIM-26 compared to VIM-1, VIM-2 and VIM-7 for the 
cephalosporins and carbapenem substrates that all fill the R2 site upon biding. 
 
Docking of the poorly catalyzed substrate ceftazidime (Figure 1) into VIM-26 showed more space in 
the R2 site with no hydrophobic nor polar interactions from the substrate to the VIM-26 enzyme. 
This could possibly reflect the low binding affinity found in our kinetics analysis (Table 1). The docking 
result does not, however, explain why the cephalosporins with positively charged or polar R2 groups 
are poorly catalyzed by VIM-26 with its neutral pocket for R2 binding. Phe61 and Asn233 in VIM-26 
generate a “lid” over the metal binding site in all four VIM-26 structures. This is very different from 
what has been reported in VIM-2 (also with Phe61 and Asn233) and VIM-7 (with Leu61 and 
Asn233)(Figure 4a,b,c) where the entrance to metals in the active site is more accessible. Although 
this cannot be observed in our four VIM-26 crystal structures, we hypothesize that Phe61 and 
Asn233 can dissociate, and thereby open up the entry to the reactive metal center.  
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Conclusion  
The enzymatic characterization and MIC determinations showed that VIM-26, like VIM-7 is 
characterized with being a more efficient penicillinase than VIM-1 and VIM-2, but with lower 
cephalosporinase activity. The only difference between VIM-1 and VIM-26 is the presence of Leu224 
in VIM-26 instead of His224 in VIM-1, indicating the importance of this residue in the specificity of 
VIM-enzymes. Analysis of the determined VIM-26 crystal structures show that the L3 loop in VIM-26 
which includes Leu224 and Ser228 make the R2 drug binding site both open and neutral. Such a 
neutral R2 binding site is different from many other B1 MBLs that has a conserved lysine at position 
224 [2, 8, 12] reported to be important for binding the carboxyl group on the C-3/C-4 atom of the 
substrate. In VIM-2, VIM-4 and VIM-7, Arg228 can serve to make a similar substrate protein 
interaction as found in a VIM-2 inhibitor complex structure [15]. In contrast, VIM-26 cannot offer a 
similar positively charged residue for the substrate binding which might contribute to the specificity 
of VIM-26, and possibly explain why the penicillinase activity of VIM-26 is not affected by the 
presence of Leu224, but the cephalosporinase activity is reduced. Further, in our VIM-26-PEG 
structure the PEG molecule is found in the R1 drug binding site, surrounded by Phe61 in the L1 loop, 
Trp87, His118 and Asn233 in the L3 loop emphasizing a role of both the L1 and the L3 loops when 
binding to the enzyme.  
 
The presented VIM-26 structures and characterization of VIM-26 have given further insights into the 
relationship between sequence, structure, and activity of VIM and subclass B1 MBLs, important for 
the future inhibitor design process. 
 
MATERIALS AND METHODS 
Cloning of blaVIM-26 from Klebsiella pneumonia isolate U-60687 
The blaVIM-26 gene from a clinical Klebsiella pneumoniae isolate U-60687 [6], was amplified using the 
following primers VIM-26-NdeI: 5’-GGAATTCCATATGTTAAAAGTTATTAGTTTATTGG-3’ and VIM-26-
BamHI: 5’-CGCGGATCCCTACTCGGCGACTGAGCGATTTTTGTG-3’ (NdeI and BamHI restriction sites are 
indicated as bold and underscored bases). The PCR product was purified from the agarose gel using 
the QIAquick Gel extraction kit (Qiagen), digested with NdeI (NEB) and BamHI (NEB), and ligated into 
the pET-26b expression vector (Novagen), generating the plasmid pET26b:VIM-26.  
 
Expression and purification of VIM-26  
VIM-26 was expressed and purified from the periplasm as previously described relying on the native 
leader sequence for transport [9, 13, 34]. In short, the pET26b:VIM-26 was transformed into E. coli 
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BL21(DE3) (Novagen). Transformed bacteria were grown in Terrific Broth supplemented with 50 mg/L 
kanamycin (Sigma) at 37°C. Expression was induced at mid log phase by addition of 0.1 mM 
isopropyl-β-D-thiogalactopyranoside (Sigma). The cells were harvested by centrifugation (4500 rpm, 
30 min at 4C) four hours after induction. Recombinant VIM-26 was purified from the periplasm 
followed by ion exchange chromatography on a Q-Sepharose HP column (GE Healthcare) and size 
exclusion chromatography on a Superdex 200 column (GE Healthcare). Buffer A (50 mM Tris pH 7.2, 
100 μM ZnCl2) was used for binding during ionic exchange purification, and elution took place during 
a gradient of Buffer B (Buffer A plus 500 mM NaCl). Size exclusion was carried out in Buffer A. 
Purified VIM-26 was concentrated by ultrafiltration (3 kDa Cut off, Amicon) to a final concentration of 
16.5 mg/ml protein with >95% purity as judged from SDS-PAGE analysis and stored at 4C. The 
purified protein was subjected to MS-MS analysis for identification after purification.  
 
Enzyme kinetics on VIM-26 
The protein concentration of purified VIM-26 was determined from the absorbance at 280 nm using 
extinction coefficient 28,420 M−1 cm−1 calculated from the amino acid sequence at the ProtParam 
tool at the ExPASy Bioinformatics Resource Portal [www.expasy.org] and a theoretical molecular 
weight of 25,891 daltons assuming cleavage of the leader sequence at residue Ala20 (Ala16 
according to class B β-lactamase (BBL) numbering [35]) as predicted from the SignalP 4.1 Server 
http://www.cbs.dtu.dk/services/SignalP/  
 
Steady-state enzyme kinetic measurements were completed at 25°C in UV-transparent 96-well plates 
(Corning) using a SpectraMax 190 spectrophotometer (Molecular Devices) in 50mM HEPES pH 7.2, 
100 μM ZnCl2, 0.1 mg/mL bovine serum albumin and 1-10 nM VIM-26. Extinction coefficients for 96-
well plates were calculated from standard curves constructed from absorbance measurements of 
serially diluted unhydrolyzed and completely hydrolyzed substrates. The tested substrates (Figure 1) 
benzylpenicillin, ampicillin, cefepime, ceftazidime, cefoxitin, cefuroxime, ertapenem, imipenem and 
meropenem were purchased from Sigma-Aldrich, Panpharma or AppliChem. For each substrate KM 
(μM) and kcat (s−1) were determined from plots of initial velocity of hydrolysis against the substrate 
concentrations. For benzylpenicillin and ampicillin, the KM was determined as the Ki by measuring 
inhibition of hydrolysis of the reporter substrate nitrocefin (Calbiochem) across a range of penicillin 
and nitrocefin concentrations. Ki values were determined by a global (SHARED-parameter) fit of these 
multiple data sets to a competitive inhibition model. In detail [21], the Ki was determined by the plot 
of Vo/Vi versus I where Vo and Vi are the initial velocity rates of nitrocefin hydrolysis without (Vo) and 
with (Vi) inhibitor. In this case the penicillins were the inhibitors. By plotting the Vo/Vi ratio versus the 
11 | P a g e  
 
inhibitor concentration, the slope is KMs/(KMs+[S]) *Ki. Herein, KMs is the Michaelis-Menten constant of 
the substrate nitrocefin, and [S] the concentration of the substrate nitrocefin. All the kinetic data 
were fitted by nonlinear regression as implemented in the Prism program (GraphPad Software). 
 
Minimum inhibitory concentration (MIC) determination 
The bla genes encoding VIM-1, VIM-2, VIM-7 or VIM-26 were amplified using Phusion High-Fidelity 
PCR mastermix (NEB). The following primers were used for amplification: VIM-1 and VIM-26; VIM-1-
RBS-F (5’-AGGAGGGTCTTGATGTTAAAAGTTATTAGTAGT) and VIM-1-RBS-R (5’- 
CTACTACTCGGCGACTGAGCGAT), VIM-2; VIM-2-RBS-F (5’- 
AGGAGGGTTTTGATGTTCAAACTTTTGAGTAAG) and VIM-2-RBS-R (5’- CTACTCAACGACTGAGCGAT) and 
VIM-7; VIM-7-RBS-F (5’-AGGAGGGTATTGATGTTTCAAATTCGCAGCTTT) and VIM-7-RBS-R (5’-
TTACTCGGCCACCGGGCGTA). For all primers, a ribosomal binding site (RBS) was included 
(underlined), and the ATG start codon is given in bold. Products were purified as described above 
before they were blunt cloned into the pCRBluntII-TOPO vector (Invitrogen) according to the 
manufacturer’s descriptions. Clones obtained after transformation of pCRBluntII constructs into 
competent Escherichia coli TOP10 (Invitrogen) cells were selected on LB-plates containing 25 mg/L 
kanamycin (Sigma) and the correct cloning was confirmed by sequencing. The minimum inhibitory 
concentration (MIC) of the strains and TOP10 cells were determined for a panel of -lactams using 
gradient strips (Liofilchem) according to the manufacturer’s instructions. 
 
VIM-26 crystallization, data collection and structure determination  
Crystallization trials for recombinant VIM-26 were performed using in-house made screening kits and 
a Phoenix RE nanolitre crystallization robot (Rigaku), setting up 300 nl protein (16.5 mg/mL) and 300 
nl reservoir solution by the sitting drop method in 96-well MRC 2 plates containing 60 μl reservoir. 
Optimization was done using 24 well pre-greased plates (Hampton Research) by the hanging drop 
method with 500 μl reservoir solution and drops containing 1 μl reservoir and 1 μl protein. After 
optimizing, good diffracting crystals were obtained after about 1 week of incubation at room 
temperature with reservoir solutions containing 21% polyethylene glycol monomethyl ethers (PEG 
MME) 5K, 0.1 M CHES buffer at pH 9.5, 0.1 M magnesium formate and 4% glycerol. The crystals were 
cryo protected in 25% PEG MME 5 K, 0.1 M CHES buffer at pH 9.5, 0.1 M magnesium formate and 
15% glycerol or 15% ethylene glycol, and then flash frozen in liquid nitrogen. The native VIM-26 and 
VIM-26-Mono structures were only treated with the cryo, whereas two unsuccessful inhibitor soaks 
(2-6 min in cryo containing D-captopril) resulted in the VIM-26-W and VIM-26-PEG structures. The X-
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ray data were collected at BESSY-II, Berlin, at beamline BL14.1 at 100 K with a wavelength of 0.91841 
Å. All data were integrated and scaled with XDS and XSCALE [36].  
 
The phase problem of VIM-26 was solved by the molecular replacement method using the program 
PHASER [37] and the VIM-7 X-ray structure (PDB ID: 2Y8B)[9] as a search model. From the molecular 
replacement search in the space group P21 only one solution with one molecule in the asymmetric 
unit was found. The models were refined in Phenix [38] and manually built in WinCoot [39].  
 
Docking of ceftazidime into VIM-26 was done using the six reported substrate conformations for 
hydrolyzed ceftazidime that was thoroughly docked into VIM-7 and VIM-2 [9] and fitting these 
conformations into the new VIM-26 structures. In brief, the hydrolyzed ceftazidime was fitted into 
VIM-26, treating the enzyme as a rigid receptor. The aim was to obtain interactions from the 
carboxylate group on the C8 atom of ceftazidime to the Zn1 ion and from the anionic nitrogen (N5) of 
β-lactam to Zn2, which is similar to the crystal structure complex of L1 MBL with the hydrolysis 
product of moxalactam [40].  
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Figure and Tables. Figure legends:  
Figure 1 
Structural formula of -lactams. Molecular structures of different penicillins, cephalosporins and 
carbapenems with their full names and abbreviations used in the text. 
Figure 2  
The VIM-26 structure. a) Overall ribbon figure of VIM-26 with the L1 (residue 60-66) and L3 (residue 
223-240) loops in green. b) The VIM-26 active site with the two zinc ions (green) and zinc 
coordinating residues (His116, His118, His196, Asp120, Osc221, His263). The adjacent residues 
Phe61, Tyr67, Trp87, Leu224, Ser228 and Asn233 are also depicted and further described in the text. 
c) Superimposed VIM-26-Mono (blue, zinc in blue) and the di zinc VIM-26 (orange, zinc in orange).  
Figure 3  
Actives sites. Final 2Fo-Fc maps for a) VIM-26-Mono (blue at 1.5 ) and b) VIM-26 (blue at 1.5 ), c) 
VIM-26-W (blue at 1.5 ) and d) VIM-26-PEG (blue at 1.2 ). In all panels the Fo-Fc Fourier difference 
maps are show in green (+4.0 ) and red (-4.0 ), and residues and waters interacting with the zinc 
ions are labeled. 
Figure 4   
Structural comparison. Calculated electrostatic surface potentials of a) VIM-26, b) VIM-2 (PDB ID: 
1KO3) and c) VIM-7 (PDB ID: 2Y8B), all with docked ceftazidime into the active sites [9].  
 
Table legends: 
Table 1. Steady state kinetic constants for purified VIM-26 for various β-lactams, compared to 
VIM-1, VIM-2 and VIM-7.  
Table 2. MIC values for E. coli TOP10 host strain and clones harboring blaVIM-26, blaVIM-1, blaVIM-2 or 
blaVIM 
Table 3. X-ray data collection statistics for the VIM-26 structures. 
Table 4. Refinement statistics for the VIM-26 structures. 
Table 5. Zinc ligand details. a) Inter atomic distances (Å) and b) angles (°) for the Zn-ligands in the 
active site of the VIM-26-Mono, VIM-26, VIM-26-W and VIM-26-PEG structures. 
 




Figure 1 Structural formula of -lactams. 
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Figure 2 The VIM-26 structure.  
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Figure 3 Actives sites 
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Figure 4 Structural comparison.  
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Table 1. Steady state kinetic constants for purified VIM-26 for various β-




VIM-1a   VIM-2b   VIM-7c   
 
KM kcat kcat/KM KM kcat kcat/KM KM kcat kcat/KM KM kcat kcat/KM 
(µM) (s-1) (s-1 * µM-1) (µM) (s-1) (s-1 * µM-1) (µM) (s-1) (s-1 * µM-1) (µM) (s-1) (s-1 * µM-1) 
Penicillins             
Benzylpenicillin  20 ± 9 d >810   40 841 29 0.034 70 280 4 13.8 d 350 25.4 
Ampicillin  30 ± 6 d >640  21 917 37 0.04 90 125 1.4 0.56 d 38 68 
Cephalosporin             
Cefepime 520 ± 70 105  ± 8 0.2 145 549 3.8 >400 >40 0.1 14 0.255 0.018 
Ceftazidime 620 ± 90 18  ± 2 0.03 794 60 0.076 72 3.6 0.05 41.8 0.186 0.0044 
Cefoxitin >1120  13  ± 3 0.011 131 26 0.2 13 15 1.2 34 37.51 1.1 
Cefuroxime 68 ± 17 140  ± 11 2.05 42 324 7.7 20 8 0.4 9.4 9.9 1.1 
Carbapenems             
Ertapenem 280 ± 40 11.4 ± 0.5 0.04 - - - 9 0.2 0.022 10.6 3.05 0.29 
Imipenem 35 ± 4 11.3  ± 0.4 0.31 1.5 2.0 1.3 9 34 3.8 12.4 47.6 3.84 
Meropenem 175 ± 20 37.8 ± 1.4 0.22 48 13 0.27 2 5 2.5 22.4 24.5 1.09 
 
a Kinetic constants for VIM-1 taken from [21] which used initial-rate conditions and Hanes-Woolf plots.  
b Kinetic constants for VIM-2 taken from [22]. 
c Kinetic constants for VIM-7 purified from the periplasm, are taken from [14].  
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Table 2. MIC values for E. coli TOP10 host strain and clones harboring blaVIM-26, blaVIM-1, blaVIM-2 or blaVIM-7.  
 
 Minimum inhibitory concentration (MIC, mg/L) 
 Penicillins Cephalosporins Carbapenems 
Host strain/clone AMP PIP PTc CAZ CTX CXM FOX FEP MEM IPM ETP 
TOP10 4 4 8 0,5 0,12 8 4 0,063 0,032 1 0,008 
TOP10 pCRBluntII-VIM-26 >256 16 32 64 32 >256 8 2 0,125 4 0,032 
TOP10 pCRBluntII-VIM-1 >256 32 128 >256 32 >256 32 8 0,25 2 0,12 
TOP10 pCRBluntII-VIM-2 >256 16 32 8 4 128 32 0,25 0,12 0,5 0,06 
TOP10 pCRBluntII-VIM-7 32 64 8 0,5 0,25 16 4 0,12 0,06 0,5 0,016 
AMP: ampicillin; PIP: piperacillin; PTc: piperacillin-tazobactam; CAZ: ceftazidime; CTX: cefotaxime; CXM: cefuroxime; FOX: cefoxitin; FEP: cefepime: MEM: 
meropenem; IPM: imipenem; ETP: ertapenem. 
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Table 3. X-ray data collection statistics for the VIM-26 structures. 
 
X-ray statistics VIM-26-Mono VIM-26 VIM-26-W VIM-26-PEG  
PDB Entry 4UWR 4UWO 4UWP 4UWS 
Beamline BL14.1 BL14.1 BL14.1 BL14.1 
Space group P21 P21 P21 P21 






























Wavelength (Å) 0.91841 0.91841 0.91841 0.91841 
No. of unique 
reflections 
30 941 30 529 22 488 24 661 
Multiplicity 4.0 (3.4) 3.4 (3.0) 2.9 (2.2) 3.6 (2.6) 
Completeness (%) 99.5 (96.3) 99.6 (97.1) 95.1 (89.7) 96.8 (81.1) 
Mean (<I> /<I>) 17.3 (3.4) 11.8 (1.9) 11.3 (2.2) 18.6 (2.3) 
Rmerge (%) a 4.2 (53.0) 5.7 (61.8) 7.6 (48.4) 4.0 (42.4) 
Wilson B-factor (Å2) 20.5 19.6 13.4 20.8 
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 VIM-26-Mono VIM-26 VIM-26-W VIM-26-PEG 
Refinement program Phenix  Phenix Phenix Phenix 
Resolution (Å) 25.0-1.55 25-1.55 25-1.70 25-1.66 
R-factor (all reflections) (%) 15.38 15.26 15.35 15.61 
R-free (%) 18.22 18.63 19.40 20.00 
No. of non H protein atoms 1938 1913 1910 1959 
No. of water molecules 163 163 180 158 
Occupancy for Zn1/Zn2 1.0/0.0 1.0/0.50 1.0/0.50 1.0/0.30 
R.m.s.d. bond lengths (Å) 0.010 0.010 0.010 0.013 
R.m.s.d. bond angles (°) 1.24 1.23 1.26 1.30 
Average B-factor (Å2)     
 All atoms 23.20 21.44 23.85 25.34 
 Protein  20.00 22.18 23.26 24.69 
 Water molecules 34.60 34.43 35.27 36.09 
 Zn 2+ ion(s) 16.02 14.92 15.56 13.92 
Ramachandran plot     
 Favored (%) 98.0 98.6 98.6 98.3 
 Allowed (%) 2.0 1.4 1.4 1.7 
 Outliers (%) 0 0 0 0 
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Table 5. Zinc ligand details. a) Inter atomic distances (Å) and b) angles (°) 
for the Zn-ligands in the active site of the VIM-26-Mono, VIM-26, VIM-26-W 
and VIM-26-PEG structures. 
a) 








Zn1 His116 NE2 2.09 2.06 2.05 2.06 
 His118 ND1 1.98 1.89 1.81 1.89 
 His196 NE2 2.02 2.02 2.07 3.00 
 W1 (OH-) 1.90 1.93 1.92 1.97 
 W2  2.57 (3.72) 2.95  
Zn2 Asp120 OD2  2.08 2.06 1.95 
 Ocs221 OD2  1.98 1.92 1.91 
 His263 NE2  2.24 2.36 2.25 
 W1 (OH-)  2.06 2.01 2.25 
 W3   2.26 2.41 2.19 
 W4   2.11 2.19 2.27 
Zn1 Zn2  3.63 3.58 3.86 
b)  








His116 NE2 Zn1 His118 ND1 99.4 98.1 96.3 96.3 
 Zn1 His196 NE2 99.8 101.6 97.3 100.1 
 Zn1 W1 (OH-) 100.6 114.0 118.1 111.7 
 Zn1 W2 172.7 143.3 165.0  
W1 Zn1 W3  86.5 84.2 88.4 
Asp120 OD2 Zn2 Ocs221 OD2  105.3 113.3 118.1 
 Zn2 His263NE2  89.4 87.6 100.0 
 Zn2 W1 (OH-)  85.3 90.4 81.7 
His263 NE2 Zn2 W1 (OH-)  172.3 170.1 173.8 
# The Zn2 atom is absent in VIM-26-Mono. 
 
 
